United States Patent 5,994,329: Scope, Claims, Expiration, Litigation, and Bisphosphonate Patent Landscape

U.S. Patent No. 5,994,329 was a Merck patent covering intermittent oral bisphosphonate dosing, particularly once-weekly alendronate for osteoporosis. Its commercially important embodiment was a 70 mg alendronate dose administered once weekly, corresponding to the Fosamax 70 mg weekly product. The patent issued on November 30, 1999, and its enforceable term has expired. It no longer blocks generic manufacture, marketing, or sale in the United States.

The patent was strategically important because it converted a daily osteoporosis regimen into a weekly regimen while protecting the dose-frequency relationship rather than the underlying alendronate molecule. The core commercial claim was claim 23, which covered oral administration of approximately 70 mg alendronate monosodium trihydrate, on an alendronic-acid basis, once weekly for treating osteoporosis.

What does U.S. Patent 5,994,329 protect?

Patent 5,994,329 protects methods and a kit involving intermittent oral administration of bisphosphonates. The principal limitations are:

Claim element	Scope
Active ingredient	A bisphosphonate, including alendronate, risedronate, ibandronate, clodronate, etidronate, tiludronate, pamidronate, zoledronate and others
Route	Oral administration
Patient	A mammal, narrowed to humans in several dependent claims
Schedule	Once weekly, twice weekly, every two weeks, or twice monthly
Uses	Inhibiting bone resorption, treating osteoporosis, or preventing osteoporosis
Dosage form	Unit dosage
Alendronate salt	Alendronate monosodium trihydrate
Kit	At least one effective unit dosage for administration under the specified continuous schedule

The patent does not claim the chemical structure of alendronate. It claims a dosing method using known bisphosphonates. That distinction matters because the underlying alendronate compound patent and the later weekly-dosing patent had different expiration dates and infringement theories.

The patent’s most commercially significant protection was directed to the following regimen:

Alendronate monosodium trihydrate
Approximately 70 mg on an alendronic-acid active basis
Oral administration
Once weekly
Treatment of osteoporosis

That combination is recited in claims 16 through 23, with claim 23 providing the narrow product-specific method claim.

How are the 44 claims organized?

The claims form three principal method-of-treatment groups and one kit claim.

Claims 1 through 15: Bone-resorption inhibition

Claim 1 is the broad independent method claim. It covers orally administering a pharmaceutically effective amount of a bisphosphonate under one of four continuous schedules:

Once weekly
Twice weekly
Every two weeks
Twice monthly

Claim 2 identifies the covered bisphosphonates. Claim 3 narrows the scope to alendronate, while claim 4 specifies alendronate monosodium trihydrate. Claims 6 through 15 add human patients, dosing frequency, and dose ranges.

The alendronate dosing ranges in this group are:

Schedule	Claimed alendronate amount
Once weekly	About 17.5 mg to about 70 mg
Twice weekly	About 8.75 mg to about 35 mg
Every two weeks	About 35 mg to about 140 mg
Twice monthly	About 35 mg to about 140 mg

Claim 9 is the key narrow once-weekly claim for approximately 70 mg.

Claims 16 through 29: Treatment of osteoporosis

Claim 16 independently covers the same intermittent schedules when used to treat osteoporosis. Claims 17 through 23 narrow the class to alendronate and then to alendronate monosodium trihydrate in humans.

The principal treatment claims are:

Claim	Regimen
22	Human, once-weekly dosing
23	Approximately 70 mg alendronate once weekly
24-25	Twice-weekly dosing, approximately 35 mg
26-27	Every-two-week dosing, approximately 140 mg
28-29	Twice-monthly dosing, approximately 140 mg

Claim 23 was the most important claim for the weekly Fosamax regimen.

Claims 30 through 43: Prevention of osteoporosis

Claim 30 independently covers the same four dosing intervals for preventing osteoporosis. Claims 31 through 36 narrow the claims to alendronate monosodium trihydrate in human patients.

The prevention claims use lower unit doses:

Claim	Regimen
36-37	Once weekly, approximately 35 mg
38-39	Twice weekly, approximately 17.5 mg
40-41	Every two weeks, approximately 70 mg
42-43	Twice monthly, approximately 70 mg

The 35 mg once-weekly regimen corresponded to the prevention indication for postmenopausal osteoporosis.

Claim 44: Kit claim

Claim 44 covers a kit containing at least one pharmaceutically effective unit dosage of a bisphosphonate for oral administration under one of the four specified schedules.

Unlike claims 16 through 43, claim 44 does not expressly recite osteoporosis treatment or prevention. Its scope depends on how the kit, instructions, labeling, and unit doses establish the claimed administration schedule. The claim is also broader than the alendronate-specific claims because it does not identify a particular bisphosphonate or dose.

Which claims were commercially relevant to Fosamax?

The principal commercial claims were claims 22 and 23.

Claim 22 covered:

A human patient
Oral bisphosphonate administration
Once-weekly dosing
Treatment of osteoporosis

Claim 23 added:

Approximately 70 mg of alendronate monosodium trihydrate
Measured on an alendronic-acid active basis

For the prevention indication, claims 36 and 37 covered approximately 35 mg once weekly. The product-level distinction was important because Fosamax was marketed in both 70 mg weekly treatment and 35 mg weekly prevention regimens.

The claims were method claims, not composition claims. A generic tablet could therefore be chemically identical to Fosamax without infringing the patent merely by being manufactured. The infringement question focused on the generic applicant’s proposed labeling, instructions, product strength, and intended use.

How strong was the patent estate for alendronate?

The patent estate had several layers, but the layers did not have equal commercial value.

Patent layer	Function	Strategic importance
Alendronate compound patent	Protected the active pharmaceutical ingredient	Strong early protection; expired before the weekly regimen patent
Salt and formulation patents	Covered selected salts, formulations, or dosage forms	Narrower protection; dependent on claim construction
Daily dosing patents	Covered earlier administration approaches	Less relevant after weekly dosing became the commercial standard
U.S. Patent 5,994,329	Covered intermittent oral schedules	Principal protection for weekly Fosamax
Method-of-use claims	Covered treatment or prevention of osteoporosis	Depended heavily on labeling and induced-infringement theories
Kit claim	Covered packaging or unit-dose arrangements	Potentially useful but narrower and more fact-dependent

The strength of Patent 5,994,329 came from the alignment between the claims and the marketed product. The 70 mg once-weekly regimen was easy to identify, commercially important, and reflected in FDA labeling. That made the patent more valuable than a method patent directed to an obscure or noncommercial dosing interval.

Its weaknesses were equally significant:

It did not protect alendronate itself.
It depended on method-of-use infringement.
It covered broad schedules that could face written-description, enablement, obviousness, or claim-construction attacks.
Generic applicants could attempt a skinny-label strategy excluding the patented use.
The patent covered oral administration, leaving nonoral administration outside its literal scope.
The claims did not independently require a particular tablet formulation or manufacturing process.

When did Patent 5,994,329 expire?

The patent issued November 30, 1999. Its ordinary patent term ran from the relevant nonprovisional filing date and ended in the late 2010s. The patent is now expired and has no remaining blocking effect in the United States.

The patent’s historical term must be distinguished from other Fosamax exclusivity dates:

Exclusivity layer	Practical effect
Alendronate compound protection	Expired earlier than the weekly dosing patent
Patent 5,994,329	Protected intermittent oral dosing, especially weekly dosing, into the late 2010s
FDA regulatory exclusivity	Separate from patent rights and limited by statutory periods
Pediatric exclusivity	Could extend listed patent protection by six months if granted and applicable
Current status	No enforceable exclusivity remains from Patent 5,994,329

A current freedom-to-operate analysis should not treat the patent as an active barrier. The relevant question today is historical liability, including whether conduct occurred before expiration or whether an earlier settlement restricted a party’s launch date.

What was the Orange Book status of Patent 5,994,329?

Patent 5,994,329 was associated with the Fosamax weekly dosing regimen and was listed in the FDA Orange Book for relevant alendronate products. Orange Book listing was important because it required generic applicants to address the patent through an ANDA certification.

The relevant certification pathways were:

Paragraph I: No patent information was listed.
Paragraph II: The listed patent had expired.
Paragraph III: The applicant would wait until patent expiration.
Paragraph IV: The listed patent was invalid, unenforceable, or would not be infringed.

For the weekly alendronate product, a generic applicant challenging Patent 5,994,329 would have had to file a Paragraph IV certification if it sought approval before the patent’s expiration date. The certification could trigger patent litigation under the Hatch-Waxman Act.

The Orange Book listing did not itself prove validity or infringement. It created a regulatory and litigation mechanism. A patent could remain listed while facing invalidity or noninfringement challenges.

Which companies challenged the weekly Fosamax patent?

The major generic competition to Fosamax involved companies seeking approval for alendronate products, including Teva, Barr Laboratories, and Apotex. Generic applicants challenged or addressed the key Fosamax patents through Paragraph IV certifications and related litigation.

The commercial issues included:

Whether the proposed generic label induced infringement of weekly osteoporosis treatment claims.
Whether the claims were invalid as obvious in view of prior bisphosphonate dosing knowledge.
Whether the weekly regimen represented a patentable clinical improvement.
Whether a generic could omit the patented indication from its label.
Whether the generic product’s strength and dosing instructions matched the claimed regimen.

Generic entry was ultimately enabled through patent expiration, litigation outcomes, and settlement arrangements. The exact launch rights varied by applicant and product, and settlement terms were not necessarily identical across all defendants.

What Paragraph IV issues applied to this patent?

The central Paragraph IV theories were likely to fall into four categories.

Obviousness

A challenger could argue that weekly or intermittent dosing was an obvious optimization of known daily bisphosphonate therapy. The analysis would consider:

Existing pharmacokinetic and pharmacodynamic data
The long skeletal retention of bisphosphonates
Known dose-response relationships
Prior clinical studies using non-daily schedules
Whether a skilled person would have expected equivalent efficacy and safety
The predictability of reducing dosing frequency

The patent holder would respond that the claimed schedule produced a clinically meaningful regimen with maintained anti-fracture efficacy, improved convenience, and potentially better adherence.

Written description and enablement

The broad claims include many bisphosphonates and multiple dosing intervals. A challenger could argue that the specification did not adequately support every listed compound and schedule. The breadth of claims 1, 2, 16, 17, 30, and 31 created a larger vulnerability surface than the narrower alendronate claims.

Infringement

For a method patent, infringement depends on the acts performed or induced. A generic applicant could argue that:

Its label did not direct the patented weekly regimen.
The proposed product could be used for noninfringing purposes.
The label omitted a patented indication.
The dosage strength did not meet the claimed range.
The product was not packaged as the claimed kit.

The patent holder could rely on label instructions, dosage strengths, promotional materials, and the predictable use of the product to establish induced infringement.

Claim construction

The terms “continuous schedule,” “biweekly,” “twice-monthly,” “unit dosage,” and “on an alendronic acid active basis” could affect infringement and validity. “Biweekly” can be ambiguous in ordinary language, although the claim context distinguishes it from “twice-monthly.” The relevant construction would be determined in litigation based on the patent specification, prosecution history, and technical understanding.

What litigation affected Patent 5,994,329?

The patent was part of the Fosamax generic-entry litigation involving Merck and generic applicants. The litigation was linked to ANDA filings, Paragraph IV certifications, and the Hatch-Waxman 30-month stay mechanism.

The main litigation risks were:

Risk	Relevance
Invalidity	Could eliminate the weekly dosing barrier before expiration
Noninfringement	Could permit approval or launch despite an active patent
Induced infringement	Central because the patent claimed treatment methods
Label carve-out	Could avoid infringement for a patented indication
Settlement	Could establish a negotiated generic launch date
Launch at risk	Could expose the generic to damages and injunctive relief

No active infringement barrier remains today because the patent has expired. Historical settlement terms may still matter for assessing the timing of past entry, damages exposure, or conduct occurring during the patent term.

Did Patent 5,994,329 cover risedronate products?

Yes, the claims expressly include risedronate. Claims 2, 5, 17, and 20 identify risedronate and its pharmaceutically acceptable salts or esters.

That language does not mean the patent was the principal patent for Actonel or other risedronate products. A patent’s inclusion of an active ingredient creates claim scope only if the other limitations are met, including oral administration, the specified dosing interval, the relevant therapeutic use, and the unit-dose requirements where applicable.

Risedronate had its own patent estate, regulatory history, formulation issues, and litigation profile. Patent 5,994,329 therefore created a potential overlapping method claim, not a complete substitute for the risedronate patent landscape.

Did the patent create biosimilar risk?

No. Bisphosphonates are small-molecule drugs, not biologics. The relevant competitive pathway was an abbreviated new drug application, not a biosimilar application under the Public Health Service Act.

The principal competitive risks were:

Generic alendronate
Generic risedronate
Alternative bisphosphonate products
Label-based design-arounds
Nonoral or differently scheduled regimens
Formulation and manufacturing competition

Biosimilar interchangeability, biologic reference-product exclusivity, and biologic patent dance procedures were not applicable to Patent 5,994,329.

What formulation and manufacturing barriers remained?

Patent 5,994,329 did not primarily protect a manufacturing process. Its value was tied to dosing instructions and therapeutic use. Generic manufacturers therefore faced fewer formulation barriers than they would have faced under a composition or process patent.

Potentially relevant barriers included:

Preparation of alendronate monosodium trihydrate
Tablet stability and dissolution
Control of active content and impurities
Oral bioavailability and administration instructions
Packaging and labeling for weekly use
Compliance with FDA product-specific guidance
Demonstration of pharmaceutical equivalence and bioequivalence

Because alendronate has administration requirements involving water intake and avoidance of food or certain beverages, labeling accuracy was commercially important. Those instructions could also affect method-of-use infringement analysis during the patent term.

How did this patent compare with competing osteoporosis patent estates?

Product or estate	Primary protection type	Relationship to Patent 5,994,329
Fosamax	Alendronate compound, formulation, and weekly method claims	Patent 5,994,329 was the key weekly regimen patent
Actonel	Risedronate compound, formulation, and use patents	Overlap possible through risedronate language, but separate estate
Boniva	Ibandronate compound and dosing claims	Patent 5,994,329 potentially reached ibandronate schedules in broad claims
Reclast	Intravenous zoledronic acid	Oral-administration limitation generally excluded the marketed IV product
Prolia	Denosumab biologic	Different molecule, regulatory pathway, and biologic patent estate
Evista	Raloxifene small molecule	Different mechanism and patent estate

Patent 5,994,329 was strongest against products that reproduced the weekly oral alendronate regimen. It was less relevant to injectable products, non-bisphosphonate osteoporosis therapies, and products whose labeling avoided the claimed uses.

What was the revenue exposure from this patent?

The patent protected a commercially important formulation of Fosamax during the period when Merck was transitioning patients from daily to weekly treatment. Its economic value came from defending the weekly product against generic substitution, not from protecting all alendronate sales indefinitely.

Revenue exposure depended on:

The share of Fosamax prescriptions using the 70 mg weekly strength
The share of sales tied to osteoporosis treatment rather than prevention
The timing of generic ANDA approvals
The enforceability of the patent after litigation
The availability of authorized generic supply
The ability of generic applicants to use a label carve-out
Merck’s broader alendronate and Fosamax Plus D portfolio

Once Patent 5,994,329 expired, the weekly dosing regimen became available for generic competition. The patent no longer supports a current exclusivity premium.

What generic launch scenarios existed?

During the patent term, generic entry could occur through several routes:

Launch after patent expiration.
Launch after a successful Paragraph IV invalidity or noninfringement judgment.
Launch under a settlement agreement with a negotiated date.
Launch with a label carve-out excluding the patented osteoporosis use.
Launch at risk before final resolution, subject to potential damages.
Launch through an authorized generic arrangement.

The practical launch question was not simply whether a generic contained alendronate. It was whether the proposed labeling and dosage regimen practiced the claimed weekly method.

What is the current legal and commercial status?

Patent 5,994,329 is expired. It is not a current U.S. barrier to generic alendronate, generic risedronate, or other oral bisphosphonate products that otherwise satisfy FDA requirements.

The patent remains relevant for:

Historical litigation analysis
Damages periods
Settlement chronology
Orange Book and ANDA strategy
Patent valuation studies
Prior-art and obviousness analysis
Reconstruction of the Fosamax product lifecycle

It does not create current patent exclusivity, current Paragraph IV exposure, or a present-day biosimilar issue.

Key Takeaways

U.S. Patent 5,994,329 protected intermittent oral bisphosphonate dosing.
The commercially central embodiment was approximately 70 mg of alendronate monosodium trihydrate once weekly for treating osteoporosis.
Claims 22 and 23 were the principal weekly treatment claims.
Claims 36 and 37 covered the 35 mg once-weekly prevention regimen.
The patent covered methods and a kit, not the alendronate molecule itself.
The claims also recited risedronate and several other bisphosphonates.
Generic applicants faced Paragraph IV and method-of-use infringement issues during the patent term.
The patent was associated with the Fosamax Orange Book and generic-entry litigation.
Biosimilar law was not relevant because alendronate is a small-molecule drug.
Patent 5,994,329 has expired and provides no current U.S. exclusivity.

FAQs

What drug did U.S. Patent 5,994,329 protect?

It principally protected the once-weekly oral alendronate regimen marketed as Fosamax 70 mg for osteoporosis treatment. Its claims also covered other bisphosphonates and other intermittent schedules.

Did Patent 5,994,329 cover daily Fosamax?

No. The claims required once-weekly, twice-weekly, every-two-week, or twice-monthly administration. A daily regimen was outside the express dosing schedules in the claims.

Could a generic sell alendronate after this patent expired?

Yes. Expiration removed the patent-based barrier, subject to FDA approval and any other applicable patents or regulatory requirements.

Was alendronate monosodium trihydrate the same as alendronic acid?

The claims measured dosage on an alendronic-acid active basis but specified alendronate monosodium trihydrate as the salt. The two descriptions identify related forms of the active ingredient and are not interchangeable for claim-analysis purposes without applying the patent’s stated conversion basis.

Did the patent cover injectable zoledronic acid?

The broad claims list zoledronate, but the claims require oral administration. A marketed intravenous zoledronic-acid product would generally not satisfy that route limitation.

References

U.S. Patent No. 5,994,329. (1999). Methods of treating osteoporosis. U.S. Patent and Trademark Office.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. FDA.
U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term calculation. USPTO.
Federal Trade Commission. (2002). Generic drug entry prior to patent expiration: An FTC study. Federal Trade Commission.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0998292	⤷ Start Trial	CA 2006 00005	Denmark	⤷ Start Trial
European Patent Office	0998292	⤷ Start Trial	PA2006002	Lithuania	⤷ Start Trial
European Patent Office	0998292	⤷ Start Trial	91222	Luxembourg	⤷ Start Trial
European Patent Office	0998292	⤷ Start Trial	PA2006002,C0998292	Lithuania	⤷ Start Trial
European Patent Office	1175904	⤷ Start Trial	PA2007007	Lithuania	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,994,329

Summary for Patent: 5,994,329